Back to results
US 12,576,151 B2Granted
Fratricide resistant modified immune cells and methods of using the same
AssigneeBeam Therapeutics Inc.
InventorJason Gehrke
Life of this patent
Estimating the term…
Abstract
The present invention features fratricide resistant modified immune cells (e.g., T- or NK-cells) having enhanced anti-neoplasia activity and methods for producing and using the same. Methods of treating neoplasia (e.g., T- or NK-cell malignancies) using fratricide resistant modified immune cells are also provided.
Claims8
A chimeric antigen receptor (CAR) comprising:
- an anti-CD2 binding domain comprising an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 383;
- SEQ ID NO:
- 385;
- SEQ ID NO:
- 386;
- and SEQ ID NO:
- 387;
- a transmembrane domain;
- a CD2 signaling domain having at least 85% identity to an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 370;
- SEQ ID NO:
- 371;
- SEQ ID NO:
- 372;
- SEQ ID NO:
- 373;
- SEQ ID NO:
- 374;
- SEQ ID NO:
- 375;
- SEQ ID NO:
- 376;
- SEQ ID NO:
- 377;
- SEQ ID NO:
- 378;
- SEQ ID NO:
- 379;
- and SEQ ID NO:
- 380;
- a leader peptide sequence;
- and
- one or more additional signaling domains, the one or more additional signaling domains selected from a CD3ζ signaling domain, a CD28 signaling domain, and a CD137 (4-1BB) signaling domain.
33 more elements
A chimeric antigen receptor (CAR), wherein the CAR comprises any one of the following amino acid sequences:
- SEQ ID NO:
- 755;
- SEQ ID NO:
- 757;
- SEQ ID NO:
- 758;
- SEQ ID NO:
- 759;
- SEQ ID NO:
- 762;
- SEQ ID NO:
- 764;
- SEQ ID NO:
- 765;
- and SEQ ID NO:
- 766.
13 more elements
An anti-CD2 binding domain comprising an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 383;
- SEQ ID NO:
- 385;
- SEQ ID NO:
- 386;
- and SEQ ID NO:
- 387.
5 more elements
Dependencies are inferred from the claim text.